Targets › CXCL10
2 programs from 2 companies in 2 trials: 2 Phase 2; Immunology; next expected readout Dec 2027.
Pro-inflammatory cytokine that is involved in a wide variety of processes such as chemotaxis, differentiation, and activation of peripheral immune cells, regulation of cell growth, apoptosis and modulation of angiostatic effects. Plays thereby an important role during viral infections by stimulating the activation and migration of immune cells to the infected sites (By similarity). (UniProt, P02778)
Open in Phaseline: the race on CXCL10, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Edesa Biotech | EB06 CXCL10 monoclonal antibody | CXCL10 | Phase 2 | Non-Segmental Vitiligo (NSV) | Dec 2027 |
| Changchun GeneScience Pharmaceutical | Genakumab injection CXCL10 inhibitor monoclonal antibody | CXCL10 | Phase 2 | Systemic Sclerosis Associated Interstitial Lung Disease | – |
Non-Segmental Vitiligo (NSV) (1) Systemic Sclerosis Associated Interstitial Lung Disease (1)
protein or peptide (1), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.